



SINPE 2022 Riunione Monotematica Cancer & Malnutrition



# BODY COMPOSITION AND IMMUNONUTRITIONAL STATUS IN PANCREATIC CANCER PATIENTS RESECTED AFTER NEOADJUVANT THERAPY: A RETROSPECTIVE, MULTICENTER ANALYSIS

Salvatore Paiella<sup>1</sup>; Ilaria Trestini<sup>2</sup>; Danila Azzolina<sup>3</sup>; Giuseppe Malleo<sup>1</sup>; Gennaro Nappo<sup>4</sup>; Claudio Ricci<sup>5</sup>; Carlo Ingaldi<sup>5</sup>; Pier Giuseppe Vacca<sup>1</sup>; Matteo De Pastena<sup>1</sup>; Erica Secchettin<sup>1</sup>; Giulia Zamboni<sup>6</sup>; Laura Maggino<sup>1</sup>; Maria Assunta Corciulo<sup>7</sup>; Marta Sandini<sup>8</sup>; Riccardo Casadei<sup>5</sup>; Claudio Bassi<sup>1</sup>; Giancarlo Mansueto, MD<sup>6</sup>; Dario Gregori<sup>7</sup>; Michele Milella<sup>8</sup>; Alessandro Zerbi<sup>4</sup>; Luca Gianotti<sup>9</sup>; Roberto Salvia<sup>1</sup>.

1 General and Pancreatic Surgery Unit, Pancreas Institute, University of Verona, Verona, Italy 2 Dietetics Services, Hospital Medical Direction, University Hospital Trust of Verona, Verona, Italy 3 Department of Environmental and Preventive Science, University of Ferrara, Ferrara, Italy 4 Pancreatic Surgey Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy 5 Pancreatic Surgery Unit, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, University of Bologna, Italy 6 Radiology Unit, Pancreas Institute, University of Verona, Verona, Italy 7 Unit of Biostatistics, Epidemiology and Public Health, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy 8 Section of Oncology, Department of Medicine, University of Verona Hospital Trust, Verona, Italy

9 School of Medicine and Surgery, University of Milano-Bicocca, and HPB Unit, San Gerardo Hospital Monza, Italy

#### Background and aims

Neoadjuvant therapy (NAT) is used increasingly to improve resectability in pancreatic cancer (PC) patients. However, it may deteriorate patients' nutritional status, which inevitably influences postoperative outcomes and prognosis. This study aimed to evaluate the impact of body composition and immunonutritional assessment on the surgical outcome in PC patients submitted to pancreaticoduodenectomy after NAT.

# Methods

Data of locally advanced PC patients submitted to pancreaticoduodenectomy after NAT between 2012 and 2019 at four high-volume institutions were retrospectively recorded. Only patients with two CT scans (before and after NAT) and immunonutritional indexes (before surgery) available were included. Postoperative outcomes evaluated were overall morbidity, major complications (Clavien-Dindo > 2), and length of stay.

### Results

The final cohort consisted of 121 patients. Skeletal muscle index (SMI) decreased after NAT (p<0.05). Major complications occurred more frequently in patients with a lower pre-NAT SMI (p=0.035), and in those who gained in subcutaneous adipose tissue compartment during NAT (p=0.043). Patients with a gain in SMI experienced fewer postoperative major complications (p=0.002). The post-NAT muscle wasting was associated with a longer length of stay (Beta 5.1, 95%CI [1.5, 8.7], p=0.006)). An increase in SMI from 35 to 40 cm2/m2 was a protective factor regarding overall postoperative complications (OR 0.43, 95% [CI 0.21, 0.86], p<0.001). None of the immunonutritional indexes investigated predicted the postoperative outcome.

## Conclusions

Body composition changes during NAT were associated with surgical outcomes in PC patients receiving pancreaticoduodenectomy after NAT. An increase in SMI during NAT should be favored to ameliorate the postoperative outcome.



pancreatic cancer, body composition, immunonutritional status, postoperative complications.

